# SKYE catalysts: Skye Bioscience, Inc. PDUFA dates and FDA events

Canonical: https://sec-api.dev/companies/skye/catalysts

> Skye Bioscience, Inc. (SKYE) has 2 upcoming catalysts. The next is the nimacimab primary completion, November 2026.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, exact day, quarter only, half-year only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Company

| Field | Value |
| --- | --- |
| Name | Skye Bioscience, Inc. |
| Ticker | SKYE (Nasdaq) |
| SEC CIK | 1516551 |
| SIC | 2834 |
| SEC filings | https://sec-api.dev/companies/skye |

## Cash runway

Cash $4.8M as of 2026-09-30; quarterly burn $5.1M; about 2.8 months of runway at that rate (XBRL company facts, accession 0001628280-26-073810).

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| Aug 2024 | [Nimacimab trial start](https://sec-api.dev/pdufa/nimacimab) | SKYE |  | completed | "In August 2024, we initiated a 26 week Phase 2a proof-of-concept trial with a 13 week follow up, CBeyondTM for nimacimab in obesity." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1516551/000151655125000027/skye-20241231.htm)) |
| March 20, 2025 | [Skye Bioscience, Inc. earnings report](https://sec-api.dev/companies/skye/catalysts) | SKYE |  | completed | "Skye Bioscience Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1516551/000151655125000028/a250320_skyexye24financial.htm)) |
| May 8, 2025 | [Nimacimab earnings report](https://sec-api.dev/pdufa/nimacimab) | SKYE |  | completed | "Skye Bioscience Reports First Quarter 2025 Results and Highlights Nimacimab Differentiation in Obesity" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1516551/000151655125000043/skye-20250331xearningspr.htm)) |
| August 7, 2025 | [Skye Bioscience, Inc. earnings report](https://sec-api.dev/companies/skye/catalysts) | SKYE |  | completed | "Skye Bioscience Reports Second Quarter 2025 Financial Results and Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1516551/000151655125000050/skye-20250630xfinancialres.htm)) |
| Q4 2025 | [Nimacimab topline data readout](https://sec-api.dev/pdufa/nimacimab) | SKYE | overweight and obesity | delayed | "•Reiterate top-line data readout from CBeyond™ Phase 2a study of nimacimab planned late Q3/early Q4 2025" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1516551/000151655125000050/skye-20250630xfinancialres.htm)) |
| Q4 2025 | [Nimacimab interim data readout](https://sec-api.dev/pdufa/nimacimab) | SKYE |  | scheduled | "•Accelerated timeline for 26-week data to late Q3/early Q4 2025: Due to faster-than-anticipated enrollment the interim analysis has been removed and top line data is expected to be reported earlier than previously reported." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1516551/000151655125000028/a250320_skyexye24financial.htm)) |
| November 10, 2025 | [Skye Bioscience, Inc. earnings report](https://sec-api.dev/companies/skye/catalysts) | SKYE |  | completed | "SAN DIEGO, CA, November 10, 2025 -- Skye Bioscience, Inc. (Nasdaq: SKYE) ("Skye" or the "Company"), a clinical stage biotechnology company developing next-generation molecules that modulate G-protein-coupled receptors to treat obesity, overweight, and related conditions, today reported financial results for the third quarter ended September 30, 2025, along with key accomplishments and upcoming milestones." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1516551/000162828025051035/skye-20250930xfinancialres.htm)) |
| Mar 2026 | [Nimacimab trial start](https://sec-api.dev/pdufa/nimacimab) | SKYE |  | completed | "In March 2026, the Company initiated an expansion study (Part C) of the CBeyond Phase 2a trial to assess preliminary safety and pharmacokinetic (PK) profile of nimacimab administered intravenously (IV)." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1516551/000162828026073810/skye-20260930.htm)) |
| March 10, 2026 | [Skye Bioscience, Inc. earnings report](https://sec-api.dev/companies/skye/catalysts) | SKYE |  | completed | "Skye Bioscience Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1516551/000162828026016400/a260310_skyexye25financial.htm)) |
| Q3 2026 | [Nimacimab topline data readout](https://sec-api.dev/pdufa/nimacimab) | SKYE |  | scheduled | "Full topline reporting of the CBeyond Phase 2a extension data including nimacimab monotherapy data and 13-week off-therapy follow-up is expected to take place in Q3 2026." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1516551/000162828026004451/skye-20260202.htm)) |
| Q4 2026 | [Nimacimab topline data readout](https://sec-api.dev/pdufa/nimacimab) | SKYE | Obesity | scheduled | "The Company expects its current capital to fund projected operations and key clinical milestones into the fourth quarter of 2026, including topline data from the Phase 2a extension study of nimacimab and certain manufacturing and clinical activities, initial manufacturing runs needed to enable a subsequent trial, and planning activities, but excluding the anticipated clinical cost of a proposed Phase 2b study to evaluate higher doses of nimacimab and support combination development and additional anticipated drug manufacturing costs to resupply any such Phase 2b study." ([SEC Form 8-K](https://www.sec.gov/Archives/edgar/data/1516551/000162828026004451/skye-20260202.htm)) |
| Q4 2026 | [RXC008 trial start](https://sec-api.dev/pdufa/rxc008) | SKYE | fibrostenotic Crohn's disease | scheduled | "Our lead program, RXC008, is ready to commence its Phase 2 study in Q4 2026 in fibrostenotic Crohn's disease, an area of serious unmet need with no approved therapies to target the underlying fibrotic aspects of this disease; and we expect topline data in H2 2028." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1516551/000162828026056966/a260813_skyexredxxceosxscr.htm)) |
| November 2026 | [Nimacimab primary completion](https://sec-api.dev/pdufa/nimacimab) | SKYE | Obesity | scheduled | "NCT06577090 (Study to Evaluate the Effect on Obesity of QW Nimacimab and QW Nimacimab Co-administered With Semaglutide vs Placebo): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-11-20 (ESTIMATED); Lead Sponsor Skye Bioscience, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06577090)) |
| 2H 2028 | [RXC008 topline data readout](https://sec-api.dev/pdufa/rxc008) | SKYE | fibrostenotic Crohn's disease | scheduled | "On-track for first patient, first dose in Q4 2026 with Topline data expected H2 2028 Study Set Up" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1516551/000162828026056966/skye-20260814xex992xdeck.htm)) |

## Drugs

- [Nimacimab](https://sec-api.dev/pdufa/nimacimab): overweight and obesity, Obesity
- [RXC008](https://sec-api.dev/pdufa/rxc008): fibrostenotic crohn's disease

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/companies/skye/catalysts.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "SKYE catalysts: Skye Bioscience, Inc. PDUFA dates and FDA events." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/companies/skye/catalysts

```bibtex
@misc{secapidev_companies_skye_catalysts_20261116,
  title        = {SKYE catalysts: Skye Bioscience, Inc. PDUFA dates and FDA events},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/companies/skye/catalysts}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_companies_skye_catalysts_20261116","title":"SKYE catalysts: Skye Bioscience, Inc. PDUFA dates and FDA events","publisher":"sec-api.dev","URL":"https://sec-api.dev/companies/skye/catalysts","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
